MX2021014163A - Forma cristalina de bromuro de sofpironio y metodo para su preparacion. - Google Patents
Forma cristalina de bromuro de sofpironio y metodo para su preparacion.Info
- Publication number
- MX2021014163A MX2021014163A MX2021014163A MX2021014163A MX2021014163A MX 2021014163 A MX2021014163 A MX 2021014163A MX 2021014163 A MX2021014163 A MX 2021014163A MX 2021014163 A MX2021014163 A MX 2021014163A MX 2021014163 A MX2021014163 A MX 2021014163A
- Authority
- MX
- Mexico
- Prior art keywords
- crystalline form
- sofpironium bromide
- diastereomer
- sofpironium
- bromide
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/4015—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having oxo groups directly attached to the heterocyclic ring, e.g. piracetam, ethosuximide
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
- C07C59/147—Saturated compounds having only one carboxyl group and containing —CHO groups
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D207/12—Oxygen or sulfur atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Dermatology (AREA)
- Epidemiology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Pyrrole Compounds (AREA)
- Steroid Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962851880P | 2019-05-23 | 2019-05-23 | |
| PCT/JP2020/020210 WO2020235665A1 (en) | 2019-05-23 | 2020-05-22 | Crystalline form of sofpironium bromide and preparation method thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2021014163A true MX2021014163A (es) | 2022-01-04 |
Family
ID=72146250
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2021014163A MX2021014163A (es) | 2019-05-23 | 2020-05-22 | Forma cristalina de bromuro de sofpironio y metodo para su preparacion. |
Country Status (18)
| Country | Link |
|---|---|
| US (3) | US20220298108A1 (https=) |
| EP (1) | EP3972955A4 (https=) |
| JP (2) | JP6748329B1 (https=) |
| KR (1) | KR20220011671A (https=) |
| CN (1) | CN114008023B (https=) |
| AU (1) | AU2020277881B2 (https=) |
| BR (1) | BR112021023241A2 (https=) |
| CA (1) | CA3139948A1 (https=) |
| CL (1) | CL2021003047A1 (https=) |
| CO (1) | CO2021017456A2 (https=) |
| IL (1) | IL288285B1 (https=) |
| MX (1) | MX2021014163A (https=) |
| MY (1) | MY206154A (https=) |
| PH (1) | PH12021552915A1 (https=) |
| SG (1) | SG11202111678WA (https=) |
| TW (2) | TWI838531B (https=) |
| WO (1) | WO2020235665A1 (https=) |
| ZA (1) | ZA202109514B (https=) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3972955A4 (en) * | 2019-05-23 | 2023-07-05 | Kaken Pharmaceutical Co., Ltd. | CRYSTALLINE FORM OF SOFPIRONIUM BROMIDE AND ASSOCIATED METHOD OF PREPARATION |
| EP4213158A1 (en) | 2020-11-13 | 2023-07-19 | Ahead Biocomputing, Co. Ltd | Information processing device, information processing method, recording medium recording information processing program, and information processing system |
| CN115925603B (zh) * | 2022-11-29 | 2025-07-22 | 山东齐都药业有限公司 | 索吡溴铵的制备方法 |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7927613B2 (en) * | 2002-02-15 | 2011-04-19 | University Of South Florida | Pharmaceutical co-crystal compositions |
| ATE529399T1 (de) * | 2005-11-10 | 2011-11-15 | Nicholas S Bodor | Sanfte anticholinerge ester |
| ATE529400T1 (de) * | 2005-11-10 | 2011-11-15 | Nicholas S Bodor | Weiche anticholinerge zwitterionen |
| MX357741B (es) * | 2012-07-06 | 2018-07-23 | Laboratorios Senosiain S A De C V Star | Nuevas formas sólidas de inhibidores de fosfodiesterasa tipo 5. |
| US9512166B2 (en) * | 2012-09-05 | 2016-12-06 | Amri Ssci, Llc | Cocrystals of progesterone |
| US20150259283A1 (en) * | 2014-03-13 | 2015-09-17 | Brickell Biotech, Inc. | Formulation for soft anticholinergic analogs |
| US10282282B2 (en) * | 2016-06-29 | 2019-05-07 | Synopsys, Inc. | Automated HTTP user flows simulator |
| WO2018026869A1 (en) * | 2016-08-02 | 2018-02-08 | Dermira, Inc. | Processes for making, and methods of using, glycopyrronium compounds |
| EP3972955A4 (en) * | 2019-05-23 | 2023-07-05 | Kaken Pharmaceutical Co., Ltd. | CRYSTALLINE FORM OF SOFPIRONIUM BROMIDE AND ASSOCIATED METHOD OF PREPARATION |
-
2020
- 2020-05-22 EP EP20809754.3A patent/EP3972955A4/en active Pending
- 2020-05-22 TW TW109117164A patent/TWI838531B/zh active
- 2020-05-22 IL IL288285A patent/IL288285B1/en unknown
- 2020-05-22 SG SG11202111678WA patent/SG11202111678WA/en unknown
- 2020-05-22 CA CA3139948A patent/CA3139948A1/en active Pending
- 2020-05-22 JP JP2020089283A patent/JP6748329B1/ja active Active
- 2020-05-22 WO PCT/JP2020/020210 patent/WO2020235665A1/en not_active Ceased
- 2020-05-22 CN CN202080034880.8A patent/CN114008023B/zh active Active
- 2020-05-22 MY MYPI2021006212A patent/MY206154A/en unknown
- 2020-05-22 BR BR112021023241A patent/BR112021023241A2/pt unknown
- 2020-05-22 MX MX2021014163A patent/MX2021014163A/es unknown
- 2020-05-22 AU AU2020277881A patent/AU2020277881B2/en active Active
- 2020-05-22 KR KR1020217041385A patent/KR20220011671A/ko not_active Ceased
- 2020-05-22 TW TW112144978A patent/TWI870116B/zh active
- 2020-05-22 US US17/611,158 patent/US20220298108A1/en active Pending
- 2020-08-06 JP JP2020133620A patent/JP7605598B2/ja active Active
- 2020-11-25 US US17/105,376 patent/US11566000B2/en active Active
- 2020-11-26 PH PH1/2021/552915A patent/PH12021552915A1/en unknown
-
2021
- 2021-06-30 US US17/364,445 patent/US11584715B2/en active Active
- 2021-11-18 CL CL2021003047A patent/CL2021003047A1/es unknown
- 2021-11-24 ZA ZA2021/09514A patent/ZA202109514B/en unknown
- 2021-12-20 CO CONC2021/0017456A patent/CO2021017456A2/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CA3139948A1 (en) | 2020-11-26 |
| IL288285B1 (en) | 2026-02-01 |
| CN114008023A (zh) | 2022-02-01 |
| US20210395197A1 (en) | 2021-12-23 |
| AU2020277881B2 (en) | 2025-03-06 |
| CO2021017456A2 (es) | 2022-01-17 |
| WO2020235665A1 (en) | 2020-11-26 |
| ZA202109514B (en) | 2023-12-20 |
| PH12021552915A1 (en) | 2022-04-04 |
| SG11202111678WA (en) | 2021-11-29 |
| BR112021023241A2 (pt) | 2022-01-04 |
| US20220298108A1 (en) | 2022-09-22 |
| JP7605598B2 (ja) | 2024-12-24 |
| CN114008023B (zh) | 2024-02-09 |
| US11584715B2 (en) | 2023-02-21 |
| EP3972955A1 (en) | 2022-03-30 |
| MY206154A (en) | 2024-12-02 |
| CL2021003047A1 (es) | 2022-09-20 |
| IL288285A (en) | 2022-01-01 |
| AU2020277881A1 (en) | 2021-12-09 |
| JP6748329B1 (ja) | 2020-08-26 |
| TWI870116B (zh) | 2025-01-11 |
| TW202411205A (zh) | 2024-03-16 |
| TWI838531B (zh) | 2024-04-11 |
| US20210171460A1 (en) | 2021-06-10 |
| JP2020189839A (ja) | 2020-11-26 |
| EP3972955A4 (en) | 2023-07-05 |
| JP2020189856A (ja) | 2020-11-26 |
| KR20220011671A (ko) | 2022-01-28 |
| TW202110796A (zh) | 2021-03-16 |
| US11566000B2 (en) | 2023-01-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CO2021017456A2 (es) | Forma cristalina de bromuro de sofpironio y método para su preparación | |
| PH12021552083A1 (en) | Fused tricyclic compounds useful as anticancer agents | |
| ZA202007671B (en) | Pharmaceutical combination, composition, and combination formulation containing glucokinase activator and biguanide hypoglycemic drug as well as preparation method and use thereof | |
| CA2649022A1 (en) | Cocrystal of c-glycoside derivative and l-proline | |
| MX2022008066A (es) | Compuestos triciclicos sustituidos. | |
| CR20200532A (es) | Compuestos de heteroarilo tetracíclicos | |
| IL292161B1 (en) | New methylquinazolinone derivatives | |
| RU2014102773A (ru) | Новые кристаллические формы ингибиторов дипептидилпептидазы-iv | |
| TN2018000395A1 (en) | New (hetero)aryl-substituted-piperidinyl derivatives, a process for their preparation and pharmaceutical compositions containing them | |
| WO2014209841A3 (en) | Compounds for treating spinal muscular atrophy | |
| GEP20125579B (en) | Novel crystalline form vi of agomelatine, preparation method thereof and pharmaceutical compositions containing same | |
| MY150519A (en) | Imidazoquinolines with immuno-modulating properties | |
| FI3383392T3 (fi) | Annosteluohjelmat 2-hydroksi-6-((2-(1-isopropyyli-1h-pyratsol-5-yyli)pyridin-3-yyli)metoksi)bentsaldehydille | |
| JP2014511840A5 (https=) | ||
| JP2015533181A5 (https=) | ||
| MX2022006470A (es) | Tiromimeticos novedosos. | |
| MY139508A (en) | §-crystalline form of ivabradine hydrochloride, a process for its preparation and pharmaceutical compositions containing it | |
| AU2018251118A8 (en) | Pharmaceutical composition containing MOR agonist and KOR agonist, and uses thereof | |
| FI4003532T3 (fi) | 7-kloori-2-(4-(3-metoksiatsetidin-1-yyli)sykloheksyyli)-2,4-dimetyyli-n-((6-metyyli-4-(metyylitio)-2-okso-1,2-dihydropyridin-3-yyli)metyyli)bentso[d][1,3]dioksoli-5-karboksamidin kiteisiä muotoja | |
| BR112022009705A2 (pt) | Forma cristalina anidra de um derivado de ácido 7h-benzo[7]anuleno-2-carboxílico, seus usos e processos de preparação, forma sólida, medicamento e composição farmacêutica | |
| RU2017142958A (ru) | Кристаллы азабициклического соединения | |
| WO2009140341A3 (en) | Atorvastatin compositions | |
| BR112022001568A2 (pt) | Composto, método para preparação do composto, composição farmacêutica, e, uso do composto | |
| JP2015522037A5 (https=) | ||
| JP2016515550A5 (https=) |